333-010-0000 Cancer Reporting Regulations: Definitions (1) "Active follow-up program" means a program for a health care facility to determine, at least annually, information including but not limited to the vital status of each case. (2) "Admitted" means a rendering of any service by the health care facility to a patient under the authority or auspices of the facility's license under ORS 441.015, including but not limited to routine admission to the hospital, admission to the emergency room, or receiving services in an out-patient clinic. (3) "Authority" means the Oregon Health Authority. (4) "Central cancer registry" means the Oregon Health Authority, Public Health Division program authorized to collect, receive, and maintain cancer data for the entire state and which maintains the system by which the collected information is reported to the Division. (5) "Central Cancer Registry Notification Form" means the form required for practitioners to report a case of reportable cancer or reportable non-malignant condition. (6) "Certified tumor registrar" means an individual who passes the certification examination and is currently certified by the Council on Certification of the National Cancer Registrars Association which provides the education and skills needed to fully abstract a cancer case. (7) "Clinical laboratory" means a facility where microbiological, serological, chemical, hematological, immunohematological, immunological, toxicological, cytogenetical, exfoliative cytological, histological, pathological or other examinations are performed on material derived from the human body, for the purpose of diagnosis, prevention of disease or treatment of patients by physicians, dentists and other persons who are authorized by license to diagnose or treat humans. (8) "Date of diagnosis" means the date of initial diagnosis by a practitioner for the cancer being reported. (9) "Division" means the Public Health Division of the Oregon Health Authority. (10) "First course of treatment" means all methods of treatment recorded in the treatment plan and administered to a person with a case of reportable cancer or reportable non-malignant condition before disease progression or recurrence, as defined in the American College of Surgeons Commission on Cancer Oncology Registry Data Standards Manual that is for the current year of diagnosis. (11) "Health care facility" means a hospital, as defined in ORS 442.015, or an ambulatory surgical center, as defined in ORS 442.015 or any other facility in which patients are diagnosed or provided treatment for cancer or benign or borderline tumors of the brain and central nervous system. (12) "Health system cancer registry" means a cancer registry maintained by a health system that includes all reportable cancer cases occurring in the population served by the health system, whether or not the cases are diagnosed or treated in the health system’s health care facilities. (13) "OSCaR" means the Oregon State Cancer Registry and has the same meaning as "central cancer registry". (14) "Practitioner" means any person whose professional license allows the person to diagnose or treat cancer patients. (15) "Quality control system" means operational procedures by which the accuracy, completeness, and timeliness of the information reported to OSCaR can be determined and improved. (16) "Reportable cancer" means all malignant neoplasms including carcinoma in situ, except basal and squamous cell carcinoma of the skin, carcinoma in situ of the cervix uteri, CIN III (diagnosed on or after January 1, 1996), and PIN III (diagnosed on or after January 1, 2001). (17) "Reportable Cancer Data Items List" means the list of variables for reportable cancers and reportable non-malignant conditions reported by health care facilities following the recommendations of the Centers for Disease Control and Prevention National Program of Cancer Registries ("CDC-NPCR") and further defined by the North American Association of Central Cancer Registries ("NAACCR") Data Standards and Data Dictionary, available on the Oregon State Cancer Registry website: www.healthoregon.org/oscar. (18) "Reportable non-malignant condition" means benign or borderline tumors of the brain (including the meninges and intracranial endocrine structures) and central nervous system, diagnosed on or after January 1, 2004. (19) "Reportable pre-malignant condition" means all high-grade squamous intraepithelial lesion (CIN 2,3) and adenocarcinoma in situ (AIS) of the uterine cervix, high-grade squamous intraepithelial lesion of the vagina and vulva (VAIN 2,3/VIN 2,3), and high-grade squamous intraepithelial lesion (AIN 2,3) and carcinoma in situ of the anus. (20) "Special study" means a Division-sponsored project that explores a particular facet of cancer incidence, morbidity, or mortality including, but not limited to, exploring hypotheses of disease risk, treatment options or cancer control authorized under ORS 432.520. Statutory/Other Authority: ORS 432.500, 432.510 & 432.540 Statutes/Other Implemented: ORS 432.510, 432.520 & 432.540 History: PH 20-2017, amend filed 12/21/2017, effective 01/01/2018 PH 13-2011, f. 12-28-11, cert. ef. 1-1-12 OHD 7-1998, f. 7-14-98, cert. ef. 8-1-98 HD 2-1996, f. & cert. ef. 2-29-96